Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells $12,581.14 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $12,581.14. Following the completion of the sale, the chief operating officer now owns 336,136 shares of the company’s stock, valued at $6,137,843.36. This trade represents a 0.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fulgent Genetics Trading Up 1.0 %

Fulgent Genetics stock traded up $0.18 during mid-day trading on Wednesday, hitting $18.07. The company’s stock had a trading volume of 155,004 shares, compared to its average volume of 185,564. Fulgent Genetics, Inc. has a 1 year low of $16.56 and a 1 year high of $30.68. The stock’s fifty day moving average is $20.05 and its two-hundred day moving average is $21.18.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System purchased a new position in shares of Fulgent Genetics during the first quarter worth $178,000. Vanguard Group Inc. boosted its position in shares of Fulgent Genetics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,424,448 shares of the company’s stock worth $30,911,000 after buying an additional 8,257 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of Fulgent Genetics by 11.0% during the first quarter. CANADA LIFE ASSURANCE Co now owns 29,103 shares of the company’s stock worth $631,000 after buying an additional 2,879 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Fulgent Genetics by 32.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,261 shares of the company’s stock worth $310,000 after buying an additional 3,458 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Fulgent Genetics by 36.4% during the second quarter. SG Americas Securities LLC now owns 12,826 shares of the company’s stock worth $252,000 after buying an additional 3,425 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on FLGT. Piper Sandler dropped their price target on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. StockNews.com lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.